AC Immune SA (ACIU)

NASDAQ · Health care · Pharmaceutical Preparations · Financial statements, TTM figures and earnings dates

In fiscal year 2025 (ended December 31, 2025), AC Immune SA reported revenue of CHF 3.6M and net income of −CHF 70.4M. Annual financial statements are available for fiscal years 2015 to 2025, taken from the company's filings with the SEC.

Open interactive financials →

Key financials

CHF	FY2025 2025-12-31	FY2024 2024-12-31	FY2023 2023-12-31	FY2022 2022-12-31	FY2021 2021-12-31
Income statement
Revenue	CHF 3.6M	CHF 27.3M	CHF 14.8M	CHF 3.9M	CHF 0
Operating income	−CHF 69.3M	−CHF 52.4M	−CHF 53.6M	−CHF 70.8M	−CHF 79.0M
Net income	−CHF 70.4M	−CHF 50.9M	−CHF 54.2M	−CHF 70.8M	−CHF 73.0M
Diluted EPS	−CHF 0.70	−CHF 0.51	−CHF 0.64	−CHF 0.85	−CHF 0.97
Cash flow
Operating cash flow	−CHF 69.3M	CHF 65.8M	−CHF 60.4M	−CHF 73.6M	−CHF 65.7M
Capital expenditure	CHF 900.0K	CHF 576.0K	CHF 801.0K	CHF 1.2M	CHF 2.6M
Free cash flow	−CHF 70.2M	CHF 65.3M	−CHF 61.2M	−CHF 74.8M	−CHF 68.3M
Balance sheet
Cash and equivalents	CHF 26.8M	CHF 36.3M	CHF 78.5M	CHF 31.6M	CHF 82.2M
Total assets	CHF 154.3M	CHF 230.9M	CHF 182.8M	CHF 185.9M	CHF 261.4M
Total liabilities	CHF 109.4M	CHF 118.6M	CHF 22.2M	CHF 16.9M	CHF 29.5M
Shareholders' equity	CHF 44.9M	CHF 112.3M	CHF 160.6M	CHF 169.0M	CHF 232.0M

TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in CHF as reported; per-share data adjusted for stock splits.

Annual reports

More on the interactive page

The full ACIU page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, the statements exactly as filed with the SEC, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.

Open ACIU financials →